EUVIMEDEUVIMED entdecken
Crossref

Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies

Sangyeon Won, Minjoong Kim, Seungyeon Yang, Jiyoon Seo, Minbeom Ko, Eun Kyung Lee, Seung Min Jeong

Biochemical and Biophysical Research Communications · 2026

DOI: 10.1016/j.bbrc.2025.153167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Sangyeon Won und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Medical Science, Graduate …. Hauptthemen laut MEDLINE: Cellular Senescence, Nuclear Proteins, DNA Damage, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Military Institute of Science and Technology, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular senescence is a stable growth arrest commonly triggered in cancer cells by chemotherapy or radiotherapy. Although therapy-induced senescence (TIS) initially suppresses tumor proliferation, the persistence of senescent cells can promote relapse and therapeutic resistance. Here, we identify Sestrin2 as a critical regulator of senescent cancer cell survival following DNA-damaging therapies. Sestrin2 expression is robustly induced in TIS cancer cells in a p53-dependent manner. Genetic depletion of Sestrin2 selectively impairs the viability of senescent, but not proliferating, cancer cells. Mechanistically, Sestrin2 knockdown amplifies SASP gene expression and NF-κB activation, leading to endoplasmic reticulum (ER) stress and apoptotic cell death. Importantly, Sestrin2 depletion consistently enhances the elimination of senescent cancer cells across diverse genotoxic therapies. These findings reveal a pivotal pro-survival role for Sestrin2 in TIS cancer cells and highlight its potential as a therapeutic target to improve the efficacy of DNA-damaging cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cellular SenescenceNuclear ProteinsDNA DamageNeoplasmsHumansCell SurvivalCell Line, TumorApoptosisEndoplasmic Reticulum StressTumor Suppressor Protein p53Gene Knockdown TechniquesSestrins

Stichwörter der Autor:innen

DNA damageEndoplasmic reticulum stressSestrin2Therapy-induced senescence

Substanzen

SESN2 protein, humanNuclear ProteinsTumor Suppressor Protein p53Sestrins

Autor:innen und Institutionen

  • Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Medical Science, Graduate School of the Catholic University of Korea, Seoul, Republic of Korea;…
  • Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Institute for Aging and Metabolic Diseases, College of Medicine, The Catholic University of Korea, Seoul, Repu…

Förderung

  • Military Institute of Science and Technology
  • National Research Foundation of Korea

Zitieren

APA

Won, S., Kim, M., Yang, S., Seo, J., Ko, M., Lee, E. K., & Jeong, S. M. (2026). Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.153167

Vancouver

Won S, Kim M, Yang S, Seo J, Ko M, Lee EK, et al. Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2025.153167

BibTeX
@article{Won2026,
  author = {Won, Sangyeon and Kim, Minjoong and Yang, Seungyeon and Seo, Jiyoon and Ko, Minbeom and Lee, Eun Kyung and Jeong, Seung Min},
  title = {Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2026},
  doi = {10.1016/j.bbrc.2025.153167}
}
Kostenlos starten →